Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1632 1636 3774
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18949619 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | Final Rejection | President and Fellows of Harvard College |
| 17616295 | NON-HUMAN ANIMALS HAVING A LIMITED LAMBDA LIGHT CHAIN REPERTOIRE EXPRESSED FROM THE KAPPA LOCUS AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17259766 | COMPOSITIONS AND METHODS FOR REPROGRAMMING SKIN INTO INSULIN PRODUCING TISSUE | Final Rejection | Ohio State Innovation Foundation |
| 19298798 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16428138 | Methods and Compositions for Treating Dystroglycanopathy Disorders | Non-Final OA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL |
| 19095986 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | Non-Final OA | Akouos, Inc. |
| 17555320 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS USING RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18915348 | METHODS FOR PREPARING ENGINEERED MICROVESSELS AND APPLICATIONS THEREOF | Final Rejection | ARMY MEDICAL UNIVERSITY |
| 18164502 | CELLS AND METHODS OF USES AND MAKING THE SAME | Non-Final OA | Washington University |
| 17775780 | ENHANCER POLYNUCLEOTIDE RESPONDING TO HEART FAILURE AND EXPRESSION VECTOR INCLUDING SAID ENHANCER POLYNUCLEOTIDE | Final Rejection | OSAKA UNIVERSITY |
| 17584547 | CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATORY DOMAINS | Non-Final OA | H.Lee Moffitt Cancer Center and Research Institute, Inc. |
| 18041244 | Autologous, prevascularized breast tissue constructs produced in a 3D printing method, and methods for producing same | Non-Final OA | Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
| 17636152 | SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 17783381 | TGFbeta1 Hyperactivation Causes Gender-Specific Calcific Aortic Stenosis | Final Rejection | University of South Carolina |
| 18162043 | Animal Models and Therapeutic Molecules | Final Rejection | Kymab Limited |
| 16905537 | Animal Models and Therapeutic Molecules | Non-Final OA | Kymab Limited |
| 18426803 | SELECTIVE CELL TARGETING USING ADENOVIRUS AND CHEMICAL DIMERS | Non-Final OA | Salk Institute for Biological Studies |
| 17913937 | COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS | Non-Final OA | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | Final Rejection | Editas Medicine, Inc. |
| 18526713 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | Final Rejection | BLUEALLELE CORPORATION |
| 18526808 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | Final Rejection | BLUEALLELE CORPORATION |
| 18526826 | METHODS FOR TARGETED INSERTION OF DNA IN GENES | Final Rejection | BLUEALLELE CORPORATION |
| 18557414 | TRANSGENIC RODENTS EXPRESSING CHIMERIC EQUINE-RODENT ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | TRIANNI, INC. |
| 18549437 | BIODEGRADABLE POLYMER SUPPORT CONTAINING BIOACTIVE MATERIAL AND MANUFACTURING METHOD THEREFOR | Final Rejection | CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18181796 | MUSCLE-SPECIFIC HYBRID PROMOTER | Non-Final OA | Aldevron, L.L.C. |
| 18178282 | PIG XENOTRANSPLANTS INTO HUMANS WITHOUT CHRONIC IMMUNOSUPPRESSION | Non-Final OA | NUGIFT MEDICAL LLC |
| 17685674 | GENETICALLY ENCODED CELL DEATH INDICATORS AND METHODS OF USE | Final Rejection | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
| 18047255 | TREATMENT OF RPE65-ASSOCIATED EYE DISEASES AND DISORDERS | Non-Final OA | HuidaGene Therapeutics Co., Ltd. |
| 17910125 | GENE THERAPY TREATMENT | Final Rejection | University of Sheffield |
| 17909294 | ANIMAL PREPARATION METHOD | Non-Final OA | Mingceler Biotechnology Co., Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy